FDA expands essential thrombocythemia care - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

  • By

  • Kathryn Wighton

  • September 1, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia.

Approach:
  • FDA Approval: The FDA approved ropeginterferon alfa-2b-njft for adults with essential thrombocythemia, including newly diagnosed patients.
  • Clinical Trial Data: Approval based on data from the global phase 3 SURPASS ET trial showing higher durable response rates compared to anagrelide.
Key Findings:
  • First new FDA-approved treatment for essential thrombocythemia in nearly 30 years.
  • Ropeginterferon alfa-2b-njft reduces thromboembolic events over 12 months.
  • Durable responses based on modified European Leukemia Net criteria.
Interpretation:

Ropeginterferon alfa-2b-njft is intended to lower platelet counts and disease burden.

Limitations:
  • Boxed warning for potentially fatal neuropsychiatric, autoimmune, ischemic, and infectious disorders.
  • Contraindications include severe depression, hypersensitivity to interferons, and active serious autoimmune disease.
Conclusion:

Ropeginterferon alfa-2b-njft is expected to be available in the US immediately following approval.

Sources:

Original Source(s)

FDA expands essential thrombocythemia care

  • by Kathryn Wighton

  • September 1, 2026

Related Content

FDA approves first therapy for symptomatic dermographism

The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.

FDA, CMS target gene therapy barriers

FDA and CMS initiatives aim to simplify gene therapy approvals and expand access to treatments for rare diseases.

Endometrial cancer drug cuts progression or death risk 41%

FDA grants Priority Review following improved survival versus chemotherapy in phase 3 trial.